Evidence map›Paper›PMID 42156950›Full record

ArticleNature microbiology2026

Transcription attenuation amplifies collateral vulnerabilities in rifampicin-resistant Mycobacterium tuberculosis.

Kathryn A Eckartt, Vanisha Munsamy-Govender, Stefany Quiñones-Garcia, Michael A DeJesus, Xiangwu Ju, Shixin Liu, Jeremy M Rock

Abstract read
In one paragraph

Article in Nature microbiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Kathryn A Eckartt *Laboratory of Host-Pathogen Biology, The Rockefeller University, New York, NY, USA.
Vanisha Munsamy-Govender *Laboratory of Host-Pathogen Biology, The Rockefeller University, New York, NY, USA.ORCID http://orcid.org/0009-0007-0925-9632
Stefany Quiñones-GarciaLaboratory of Host-Pathogen Biology, The Rockefeller University, New York, NY, USA.
Michael A DeJesusLaboratory of Host-Pathogen Biology, The Rockefeller University, New York, NY, USA.ORCID http://orcid.org/0000-0003-3867-0299
Xiangwu JuLaboratory of Nanoscale Biophysics and Biochemistry, The Rockefeller University, New York, NY, USA.ORCID http://orcid.org/0000-0002-7831-0899
Shixin LiuLaboratory of Nanoscale Biophysics and Biochemistry, The Rockefeller University, New York, NY, USA.ORCID http://orcid.org/0000-0003-4238-7066
Jeremy M RockLaboratory of Host-Pathogen Biology, The Rockefeller University, New York, NY, USA. rock@rockefeller.edu.ORCID http://orcid.org/0000-0002-9310-951X

Funding

Stavros Niarchos Foundation (SNF) N/AU.S. Department of Health & Human Services | National Institutes of Health (NIH) 1DP2AI144850-01
6 · The paper itself

Abstract

Mycobacterium tuberculosis (Mtb) acquires resistance to rifampicin (Rif) through mutations in the β-subunit of RNA polymerase (RNAP) that prevent the drug from binding. The most common mutation is a single amino acid substitution, βS450L, that confers antibiotic resistance. This mutation also results in collateral effects that impact bacterial physiology and fitness, although the mechanisms underlying many of these effects remain unclear. Here we employed a CRISPRi comparative functional genomics approach to analyse gene vulnerability differences between βS450L Mtb and two alternative Rif-resistant (RifR) Mtb strains, βD435V and βH445Y. Among the strongest βS450L-specific vulnerabilities, we identified thiamine and branched-chain amino acid (BCAA) biosynthesis pathways. These vulnerabilities arise, at least in part, due to transcription attenuation, which impairs βS450L Mtb's ability to upregulate expression of the critical BCAA biosynthetic enzyme ilvB1 in response to genetic or chemical inhibition. Together, our findings highlight the distinct physiological impacts of RifR in Mtb, identify transcription attenuation as a key driver of βS450L-specific vulnerabilities, and suggest potential avenues for targeted intervention.

Indexed as

Drug Resistance, BacterialMycobacterium tuberculosisRifampinTranscription, GeneticAmino Acids, Branched-ChainAmino Acid SubstitutionAntibiotics, AntitubercularBacterial ProteinsDNA-Directed RNA PolymerasesGene Expression Regulation, BacterialMutationAmino Acids, Branched-ChainAntibiotics, AntitubercularBacterial ProteinsDNA-Directed RNA PolymerasesRifampin

Identifiers

PMID42156950
PMCPMC13236596

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.